Transcription of NEW DRUG LISTING & PRICING POLICIES IN CHINA
{{id}} {{{paragraph}}}
Example: marketing
NEW DRUG LISTING & PRICING POLICIES IN CHINA
NEW drug LISTING & PRICING POLICIES IN CHINAHow to survive and thrive in the new market access environmentYANG XIE, PHD, MPH, Principal, HEOR/RWE, IQVIAIQVIA | 2 Since the year 2000, updates to CHINA s National Reimbursement drug List (NRDL) have been less frequent, with the last revision dating back to 2009. In early 2017, the Chinese Ministry of Human Resources and Social Security (MoHRSS) ended that long interval with an update that is noteworthy not only for its comprehensiveness, but also for its novel approach to negotiating PRICING for premium-priced drugs, the majority of which are manufactured by multi-national companies (MNCs). For the first time, the Ministry has begun to consider pharmacoeconomic and budget-impact evidence in its decision-making, signaling the need for global companies to approach the Chinese market differently in future.
pricing for “premium-priced” drugs, the majority of which are manufactured by multi-national companies (MNCs). For the first time, the Ministry has begun to consider pharmacoeconomic and budget-impact evidence in its decision-making, signaling the need for global companies to approach the Chinese market differently in future.
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: